These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 38180028)

  • 21. New tuberculosis vaccines in India: Modelling the potential health and economic impacts of adolescent/adult vaccination with M72/AS01
    Clark RA; Weerasuriya CK; Portnoy A; Mukandavire C; Quaife M; Bakker R; Scarponi D; Harris RC; Rade K; Mattoo SK; Tumu D; Menzies NA; White RG
    medRxiv; 2023 Jul; ():. PubMed ID: 36865172
    [TBL] [Abstract][Full Text] [Related]  

  • 22.
    Clemmensen HS; Dube JY; McIntosh F; Rosenkrands I; Jungersen G; Aagaard C; Andersen P; Behr MA; Mortensen R
    mBio; 2021 Apr; 12(2):. PubMed ID: 33879592
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CD4+ T Cells Recognizing PE/PPE Antigens Directly or via Cross Reactivity Are Protective against Pulmonary Mycobacterium tuberculosis Infection.
    Sayes F; Pawlik A; Frigui W; Gröschel MI; Crommelynck S; Fayolle C; Cia F; Bancroft GJ; Bottai D; Leclerc C; Brosch R; Majlessi L
    PLoS Pathog; 2016 Jul; 12(7):e1005770. PubMed ID: 27467705
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Heterologous prime-boost regimens with a recombinant chimpanzee adenoviral vector and adjuvanted F4 protein elicit polyfunctional HIV-1-specific T-Cell responses in macaques.
    Lorin C; Vanloubbeeck Y; Baudart S; Ska M; Bayat B; Brauers G; Clarinval G; Donner MN; Marchand M; Koutsoukos M; Mettens P; Cohen J; Voss G
    PLoS One; 2015; 10(4):e0122835. PubMed ID: 25856308
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Novel vaccines against M. tuberculosis].
    Okada M
    Kekkaku; 2006 Dec; 81(12):745-51. PubMed ID: 17240920
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Highly persistent and effective prime/boost regimens against tuberculosis that use a multivalent modified vaccine virus Ankara-based tuberculosis vaccine with interleukin-15 as a molecular adjuvant.
    Kolibab K; Yang A; Derrick SC; Waldmann TA; Perera LP; Morris SL
    Clin Vaccine Immunol; 2010 May; 17(5):793-801. PubMed ID: 20357059
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Design of a peptide-based vaccine from late stage specific immunogenic cross-reactive antigens of PE/PPE proteins of Mycobacterium tuberculosis.
    Medha ; Priyanka ; Sharma S; Sharma M
    Eur J Pharm Sci; 2022 Jan; 168():106051. PubMed ID: 34744006
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A lipidated bi-epitope vaccine comprising of MHC-I and MHC-II binder peptides elicits protective CD4 T cell and CD8 T cell immunity against Mycobacterium tuberculosis.
    Rai PK; Chodisetti SB; Maurya SK; Nadeem S; Zeng W; Janmeja AK; Jackson DC; Agrewala JN
    J Transl Med; 2018 Oct; 16(1):279. PubMed ID: 30305097
    [TBL] [Abstract][Full Text] [Related]  

  • 29. First-in-human trial of the post-exposure tuberculosis vaccine H56:IC31 in Mycobacterium tuberculosis infected and non-infected healthy adults.
    Luabeya AK; Kagina BM; Tameris MD; Geldenhuys H; Hoff ST; Shi Z; Kromann I; Hatherill M; Mahomed H; Hanekom WA; Andersen P; Scriba TJ; ; Schoeman E; Krohn C; Day CL; Africa H; Makhethe L; Smit E; Brown Y; Suliman S; Hughes EJ; Bang P; Snowden MA; McClain B; Hussey GD
    Vaccine; 2015 Aug; 33(33):4130-40. PubMed ID: 26095509
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CD4+ T cell cytokine responses to the DAR-901 booster vaccine in BCG-primed adults: A randomized, placebo-controlled trial.
    Masonou T; Hokey DA; Lahey T; Halliday A; Berrocal-Almanza LC; Wieland-Alter WF; Arbeit RD; Lalvani A; von Reyn CF
    PLoS One; 2019; 14(5):e0217091. PubMed ID: 31120957
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Modelling the health and economic impacts ofM72/AS01
    Sumner T; Clark RA; Mukandavire C; Portnoy A; Weerasuriya CK; Bakker R; Scarponi D; Hatherill M; Menzies NA; White RG
    Vaccine; 2024 Feb; 42(6):1311-1318. PubMed ID: 38307747
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety and immunogenicity of an adjuvanted protein therapeutic HIV-1 vaccine in subjects with HIV-1 infection: a randomised placebo-controlled study.
    Harrer T; Plettenberg A; Arastéh K; Van Lunzen J; Fätkenheuer G; Jaeger H; Janssens M; Burny W; Collard A; Roman F; Loeliger A; Koutsoukos M; Bourguignon P; Lavreys L; Voss G
    Vaccine; 2014 May; 32(22):2657-65. PubMed ID: 24144472
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Vaccine potential of ESAT-6 protein fused with consensus CD4
    Choi SY; Kwon KW; Kim H; Choi HH; Shin SJ
    Biochem Biophys Res Commun; 2018 Sep; 503(4):2195-2201. PubMed ID: 29894686
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Intranasal Immunization with DnaK Protein Induces Protective Mucosal Immunity against Tuberculosis in CD4-Depleted Mice.
    Chuang YM; Pinn ML; Karakousis PC; Hung CF
    Front Cell Infect Microbiol; 2018; 8():31. PubMed ID: 29473022
    [No Abstract]   [Full Text] [Related]  

  • 35. An adjuvanted polyprotein HIV-1 vaccine induces polyfunctional cross-reactive CD4+ T cell responses in seronegative volunteers.
    Van Braeckel E; Bourguignon P; Koutsoukos M; Clement F; Janssens M; Carletti I; Collard A; Demoitié MA; Voss G; Leroux-Roels G; McNally L
    Clin Infect Dis; 2011 Feb; 52(4):522-31. PubMed ID: 21208909
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of the safety and immunogenicity of a candidate tuberculosis vaccine, MVA85A, delivered by aerosol to the lungs of macaques.
    White AD; Sibley L; Dennis MJ; Gooch K; Betts G; Edwards N; Reyes-Sandoval A; Carroll MW; Williams A; Marsh PD; McShane H; Sharpe SA
    Clin Vaccine Immunol; 2013 May; 20(5):663-72. PubMed ID: 23446219
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Recombinant Liver Stage Antigen-1 (LSA-1) formulated with AS01 or AS02 is safe, elicits high titer antibody and induces IFN-gamma/IL-2 CD4+ T cells but does not protect against experimental Plasmodium falciparum infection.
    Cummings JF; Spring MD; Schwenk RJ; Ockenhouse CF; Kester KE; Polhemus ME; Walsh DS; Yoon IK; Prosperi C; Juompan LY; Lanar DE; Krzych U; Hall BT; Ware LA; Stewart VA; Williams J; Dowler M; Nielsen RK; Hillier CJ; Giersing BK; Dubovsky F; Malkin E; Tucker K; Dubois MC; Cohen JD; Ballou WR; Heppner DG
    Vaccine; 2010 Jul; 28(31):5135-44. PubMed ID: 19737527
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Nonlytic Fc-fused IL-7 synergizes with Mtb32 DNA vaccine to enhance antigen-specific T cell responses in a therapeutic model of tuberculosis.
    Ahn SS; Jeon BY; Park SJ; Choi DH; Ku SH; Cho SN; Sung YC
    Vaccine; 2013 Jun; 31(27):2884-90. PubMed ID: 23624092
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The safety and immunogenicity of an adenovirus type 35-vectored TB vaccine in HIV-infected, BCG-vaccinated adults with CD4(+) T cell counts >350 cells/mm(3).
    Churchyard GJ; Snowden MA; Hokey D; Dheenadhayalan V; McClain JB; Douoguih M; Pau MG; Sadoff J; Landry B
    Vaccine; 2015 Apr; 33(15):1890-6. PubMed ID: 25698492
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A defined tuberculosis vaccine candidate boosts BCG and protects against multidrug-resistant Mycobacterium tuberculosis.
    Bertholet S; Ireton GC; Ordway DJ; Windish HP; Pine SO; Kahn M; Phan T; Orme IM; Vedvick TS; Baldwin SL; Coler RN; Reed SG
    Sci Transl Med; 2010 Oct; 2(53):53ra74. PubMed ID: 20944089
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.